Next Phase Newsletter

A group of globally acting venture capital and private equity firms with an operating track record of over 30 years manages multiple funds globally. The group’s Life Science Venture arm is looking to provide seed, venture and growth capital to companies in the life science space. The firm’s investment size is highly variable depending on the stage and financial needs of each company and the firm has no target number of investments it plans to make over the next 6-9 months. The firm is willing to consider investment located globally.

The firm is a dedicated provider of venture capital to the international pharmaceutical, medical technology and healthcare diagnostics industries, hence looking to invest in companies in sectors of Medical devices, Diagnostic Tools and Platforms, and Specialty Pharmaceuticals that are later stage with strong in human data (Phase IIb and III or on the market) and have very little regulatory risk. The firm’s most recent Life Science Venture Capital Fund is a venture capital fund registered in North America, which focuses on a new investment approach to developing pharmaceutical assets in a capital efficient fashion, to a human proof-of-concept in single asset companies  that are anywhere from 12-18 months to IND to proof of concept (Phase IIa). The fund is currently most interested in small molecule therapeutics or IND-ready biologics for indications of metabolic disease, diseases of the blood, inflammation, and oncology. The firm is also willing to invest in highly differentiated biological compounds if compelling opportunities arise. The firm is also less inclined to invest into orphan indications.

The firm’s requirements for management teams vary on a case by case basis and the firm is open to discussion in this area.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global venture capital firm based in USA with additional offices throughout USA and Asia is investing from its newest fund (vintage 2017).  The firm invests broadly in the healthcare and technology sectors, in both venture and growth-stage financing rounds. Due to the firm’s large fund size, the firm generally only invests in rounds that raise $10 million or more. The firm makes investments globally.

Within healthcare, the firm focuses on biopharma, and also invests in medical devices, healthcare IT and healthcare service providers. The firm is generally not seeking opportunities in diagnostics.  In biopharma, The firm prefers to invest in companies that have obtained data from human clinical trials; however, the firm also invests in breakthrough therapeutic technologies at the preclinical stage.  In medical devices, the firm only invests in growth-stage companies with an approved product and initial revenues; the firm prefers to invest in breakthrough device technologies and avoids commodity markets.  The firm has a broad portfolio and is open to any indication area, but has a particular focus in oncology and orphan diseases, and typically does not invest in infectious diseases.

Within the service provision and IT sectors, the firm is focused on opportunities that provide cost savings to the healthcare system; in this sector, the firm’s expertise is primarily in companies that target healthcare providers as customers, but the firm is also open to considering other areas of the services/IT space.

The firm has no fixed requirements for companies or management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early stage investment firm with offices in USA and Asia focuses on facilitating the development and commercialization of high-potential, high-impact life science innovations arising from the U.S., Canada, South Korea, China and other markets that represent a significant source of opportunities for outsized value creation. The firm makes initial seed investments of US$100K – 1M and can bring in strategic capital from Asia to facilitate global development and market entry. The firm expects to make 2-3 new investments in the coming year.

Within life sciences, the firm is mostly interested in therapeutics, molecular diagnostics and digital health. The firm takes an opportunistic approach when it comes to disease areas and targets early stage innovation on the cusp of preclinical proof-of-concept or validation.

The firm is looking for capable teams developing innovative technologies. The firm works actively with entrepreneurs to devise and implement development and commercialization strategies, help assemble management personnel, and secure additional capital. For more mature opportunities, the firm will add value by using its fundraising, monetization, business development and licensing expertise to help secure investments and partnerships that will fund and expedite eventual commercialization.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm based in Taiwan is managing a healthcare fund that invests in several sectors within healthcare. The firm generally participates in Series A or B rounds and prefers a clear exit in less than 5 years. The firm is open to both leading and co-investing. Typical equity investments range from US$2-10M. The firm currently focuses 60% on Taiwan-based deals and 40% on China- and US-based deals.

The firm considers therapeutics and medical devices. Within therapeutics, the firm is open to all modalities including small molecules, biologics, cell therapy and gene therapy with a focus on cancer therapies. The firm would also consider R&D services, healthcare services, and healthcare IT products such as EMR management software. The firm seeks to invest in venture stage companies in Series A or B rounds.

The fund is looking for strong management teams with business background and a successful track record. The firm typically requests a board seat in their portfolio company. The firm collaborates with some of the top healthcare VC firms in Greater China and prefers companies that have a presence, or plan to establish one, in Taiwan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of a large corporation is a stage-agnostic investor, and makes investments from Series B to growth stage. Investments are therefore varied in size relative to the type of investment; initial allocations are most often from $5-10 million with the possibility of follow-on investments up to $20 million. The firm is open to opportunities worldwide but has previously focused on investing in the USA, Canada and Europe.

The firm focuses on four areas of innovation in healthcare; pharma services, data and analytics, digital supply chain, consumer health, value based care.

The firm is focused on financial returns in addition to how the parent corporation can potentially contribute value to the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A holding company of a large Japanese corporation focuses on healthcare as one of their main areas of interest. The mission of their venture group and corporate venture capital arm is to foster innovation across the group by investing in and partnering with strategic startups. In principle, the corporate venture capital arm is open to global opportunities and is geography and stage agnostic, but has specific preferences depending on the technology sector.

Healthcare/Medical is one of the major focus areas of the firm. The corporate venture capital arm is interested therapeutics solutions such as solutions beyond the pill (digital therapeutics) and around the pill (delivery systems etc). Therapeutics areas of interest are CNS, Autoimmune diseases, metabolic diseases, regenerative medicine, Aging related solutions and Vaccines. The corporate venture capital arm is also interested in diagnostics solutions based on genomics, metagenomics, metabolomics, healthcare ICT (biosensors etc), and medical big data.  Furthermore, medical devices for wound care, bone cement and hospital related infection treatment is also is an area of interest and is open to all classes of medical devices including 510k and PMA.

This corporate venture arm has a close, collaborative relationship with their group’s other active healthcare businesses and can also present opportunities to the pharma branch, CRO, CDMO branches as appropriate.

The firm is a flexible investor and does not require companies to have a Japan-centric angle. For medical device & digital therapeutics opportunities, the group does prefer technologies with strong promise in the US market. The venture group has a close relationship with all other business operations within the corporation, and can actively support companies by leveraging these relationships. For example, the group can help with Japan market entry and clinical trials through their business arm that specializes in clinical trials, with established CRO, CDMO, ICT services.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A major financial institution based in Western Europe is focused on life sciences. The firm both invests in venture capital funds and makes direct investments in seed-stage and early-stage companies. Typically the firm invests EUR 0.5-3 million initially, with further capital reserved for follow-on rounds. The firm primarily invests in France, but will consider opportunities in other areas of Europe.

The firm is interested in opportunities in biotech and medical devices, and may potentially invest in digital health.  The firm is not interested in diagnostics. The firm has a broad interest in early stage therapeutics, including small molecules, biologics, cell and gene therapies, and all indication areas including cardiovascular, neurology, and rare diseases.  The firm is open to investing in repurposed drugs.  The firm invests from preclinical-stage companies through to Phase II.

The firm prefers to invest in companies based in France, but will consider opportunities elsewhere in Europe: within France the firm is typically a lead investor, but in other regions The firm prefers to be a follow-on investor. The firm focuses on investing in companies which have also received an investment from a VC that the firm is invested in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.